SummaryHepatitis C virus (HCV) serine protease is a target for antiviral therapy against HCV infection, a leading cause of liver transplantation in the US. BILN2061, (1S, 4R,]nonadec-7-ene-4-carboxylic acid, is a potent inhibitor of HCV and the first compound in this class of cyclic peptides in human trials. Here, we report the synthesis of deuteriumlabeled BILN2061 with isotopic enrichment of 99%, tritium-labeled BILN2061 with a specific activity of 17.1 GBq/mmol, and carbon-14-labeled BILN2061 with a specific activity of 1.83 GBq/mmol. The isotopes were incorporated via a Hantzsch thiazole synthesis of labeled isopropyl thiourea and a-bromoketone intermediate. The preparation of labeled isopropyl thiourea is reported.